At a glance
ClinicalIndex Comparison RecordN/ACompleted· 37 enrolled
Drug / intervention
3RP-Lymphomabehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma
In Brief
A clinical study evaluating 3RP-Lymphoma for Lymphoma. Completed, enrolled 37 participants across 1 site.
Detailed Summary
The Relaxation Response Resiliency Program (3RP) was developed by researchers at the MGH Benson-Henry Institute for Mind Body Medicine; This program has recently been adapted to target the needs of individuals who have completed treatment for lymphoma (3RP-Lymphoma).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States
CollaboratorsAmerican Cancer Society, Inc.
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartAug 2017
Primary CompletionJun 2018
Study CompletionSep 2018
TodayJul 2026
First PostedJul 11, 2017
Enrollment StartAug 3, 2017
Primary CompletionJun 30, 2018
Study CompletionSep 24, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 9.0 years ago
Interventions
3RP-Lymphomabehavioral
An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals who have recently completed treatment for lymphoma.